Baird raised the firm’s price target on Regeneron to $797 from $760 and keeps a Neutral rating on the shares. The firm said high-dose Eylea got off to a quick start in its first quarter on the market, though share gains by Vabysmo and cannibalization of 2mg Eylea revenues led the overall Eylea franchise to be flat from 2Q.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on REGN:
- Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH
- Regeneron price target raised to $935 from $925 at Barclays
- Regeneron upgraded to Outperform from Market Perform at Raymond James
- Regeneron Reports Third Quarter 2023 Financial and Operating Results
- Regeneron reports Q3 adjusted EPS $11.59, consensus $10.77